MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

Home・Aandelen Lijst・Pulse Biosciences Inc

Pulse Biosciences Inc

Gesloten

SectorGezondheidszorg

14.33 3.92

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

13.7

Max

14.36

Belangrijke statistieken
By Trading Economics
Inkomsten	-217K -19M
Verkoop	86K 86K
EPS	-0.29
Winstmarge	-22,540.698
Werknemers	75
EBITDA	-228K -19M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+54.39% upside

Dividenden
By Dow Jones
Volgende Winsten	26 mrt 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-179M 958M
Vorige openingsprijs	10.41
Vorige sluitingsprijs	14.33

Nieuwssentiment

By Acuity

60%

40%

312 / 361 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

16.59 / 17.17 Steun & Weerstand

Pulse Biosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

20 jan 2026, 23:43 UTC

Marktinformatie

Gold Consolidates; May Face Technical Correction -- Market Talk

20 jan 2026, 23:42 UTC

Marktinformatie

Nikkei May Fall Amid Concerns Over U.S.-Europe Trade Relations -- Market Talk

20 jan 2026, 23:41 UTC

Winsten

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- 2nd Update

20 jan 2026, 23:29 UTC

Marktinformatie

RBA Rate Hike in February Would Be a Painful One -- Market Talk

20 jan 2026, 23:26 UTC

Marktinformatie

Global Equities Roundup: Market Talk

20 jan 2026, 23:26 UTC

Marktinformatie

James Hardie Appeals More as Reece's U.S. Strategy Comes Under Scrutiny -- Market Talk

20 jan 2026, 22:45 UTC

Acquisities, Fusies, Overnames

ACCC: Ampol-EG Deal Is First Assessment Subject to Phase 2 Review Under New Merger Control Regime

20 jan 2026, 22:45 UTC

Acquisities, Fusies, Overnames

ACCC Seeks Submissions in Response to Phase 2 Notice by February 4

20 jan 2026, 22:44 UTC

Acquisities, Fusies, Overnames

ACCC: Ampol's Offer to Sell 19 Retail Fuel Sites Doesn't Adequately Address Issues

20 jan 2026, 22:44 UTC

Acquisities, Fusies, Overnames

ACCC Identifies 115 EG Sites Where Deal Could Substantially Lessen Competition

20 jan 2026, 22:43 UTC

Acquisities, Fusies, Overnames

ACCC Says Deal Could Substantially Lessen Competition in Retail Supply of Petrol, Diesel in Several Markets in Australia

20 jan 2026, 22:43 UTC

Acquisities, Fusies, Overnames

Ampol's Acquisition of EG Australia to Undergo In-Depth Review by Competition Regulator

20 jan 2026, 22:27 UTC

Acquisities, Fusies, Overnames

Netflix Plans to Roll Out New Mobile User Interface Later This Year, Co-CEO Says

20 jan 2026, 22:25 UTC

Acquisities, Fusies, Overnames

Netflix Co-CEO Sees Uptick in Engagement for TV-Based Games

20 jan 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Netflix Would Keep 45-Day Theater Release Window for Warner Bros. Films, Co-CEO Says

20 jan 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Netflix Excited to Strengthen Warner Bros.'s Theatrical-Distribution Business, Co-CEO Says

20 jan 2026, 22:19 UTC

Acquisities, Fusies, Overnames

Netflix Pleased With Early Results for Podcasts, Co-CEO Says

20 jan 2026, 22:18 UTC

Winsten

Netflix Stock Is Falling. This Is Overshadowing the Streamer's Earnings Beat. -- Barrons.com

20 jan 2026, 22:17 UTC

Acquisities, Fusies, Overnames

Netflix's Live Events Are Boosting Retention, Co-CEO Says

20 jan 2026, 22:16 UTC

Acquisities, Fusies, Overnames

Netflix Remains 'Very Excited' About Live-Events Offering, Co-CEO Says

20 jan 2026, 22:15 UTC

Acquisities, Fusies, Overnames

Netflix's Proposed Deal for Warner Bros. Would Protect, Create Jobs, Co-CEO Says

20 jan 2026, 22:15 UTC

Acquisities, Fusies, Overnames

Netflix Competes for Attention Across Streaming, Broadcast, Cable, Gaming, Social Media, Video Platforms, Co-CEO Says

20 jan 2026, 22:13 UTC

Acquisities, Fusies, Overnames

Netflix Co-CEO: TV Landscape Has Never Been More Competitive

20 jan 2026, 22:11 UTC

Acquisities, Fusies, Overnames

Netflix Confident Warner Bros. Deal Would Pass Regulatory Review, Co-CEO Says

20 jan 2026, 22:10 UTC

Acquisities, Fusies, Overnames

Netflix Would Leverage Global Footprint, Streaming Expertise to Improve Warner Bros.'s HBO Max Service, Co-CEO Says

20 jan 2026, 22:08 UTC

Acquisities, Fusies, Overnames

Netflix Won't Raise Prices During Regulatory-Review Process for Pending Warner Bros. Deal, Co-CEO Says

20 jan 2026, 22:07 UTC

Acquisities, Fusies, Overnames

Netflix Sees Warner Bros. as Another Mechanism to Improve Offerings, Co-CEO Says

20 jan 2026, 22:06 UTC

Winsten

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- Update

20 jan 2026, 22:00 UTC

Marktinformatie

Acquisities, Fusies, Overnames

ESG Roundup: Market Talk

20 jan 2026, 21:50 UTC

Marktinformatie

Winsten

Tech, Media & Telecom Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Pulse Biosciences Inc Prognose

Koersdoel

By TipRanks

54.39% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 22 USD 54.39%

Hoogste 22 USD

Laagste 22 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Pulse Biosciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan Pulse Biosciences Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

16.59 / 17.17Steun & Weerstand

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

312 / 361 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Pulse Biosciences Inc

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.